title: Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
abstract: Objective To determine the efficacy and prognosis of autologous hematopoietic stem cell transplantation (ASCT) as frontline treatment for peripheral T cell lymphoma (PTCL). Methods Clinical data from 46 PTCL patients who achieved complete (CR) or partial remission (PR) after ASCT from October 1996 to July 2014 were analysed retrospectively. Results Median patient age was 32 (range: 15-68) years. Disease types included PTCL, unspecified type, in 23 patients, anaplastic large cell lymphoma in eight, angioimmunoblastic lymphoma in eight, extranodal NK/T-cell lymphoma in five, and hepatosplenic T-cell lymphoma and enteropathy associated T-cell lymphoma in one each. Of these patients, 80% had Prognostic Index for Peripheral T-cell Lymphoma scores ≥1. Thirty-four patients had pre-transplantation CR and 12 had PR. Median follow up was 37 (6-176) months. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 77.1% and 61.9%, respectively. Multivariate analysis showed that pre-transplantation CR was an independent risk factor for survival, and CR was more common than PR (OS 81% vs 59.3%; PFS 71.8% vs 17.8%). Conclusion Frontline consolidation treatment with ASCT was associated with favourable outcomes in patients with PTCL. Pre-transplantation CR was a prognostic factor for survival, suggesting that ASCT may be favoured as front-line consolidation therapy after first complete remission.
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Han
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Daobin
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Ruan
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Minghui
authors.initials: M
authors.lastname: Duan
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Tienan
authors.initials: T
authors.lastname: Zhu
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Huacong
authors.initials: H
authors.lastname: Cai
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Cao
authors.affiliation: Peking Union Medical College Hospital (PUMCH), Beijing, China.
authors.forename: Mingqi
authors.initials: M
authors.lastname: Ouyang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D016411:Lymphoma, T-Cell, Peripheral / Q000145:classification / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate
keywords: Autologous stem-cell transplantation; complete response; consolidation; frontline; peripheral T-cell lymphoma